Abbott Gains Pain-Relief Drug In $190M Deal

Law360, New York (November 12, 2009, 5:09 PM EST) -- Looking to expand its pain treatment portfolio and boost its expertise in biologics, Abbott Laboratories has snapped up PanGenetics BV’s experimental drug for chronic pain in a deal worth up to $190 million.

Abbott Park, Ill.-based Abbott said Thursday it has agreed to acquire the global rights to PG110 from the European biotechnology firm for an upfront payment of $170 million, plus additional milestone payments of up to $20 million if the drug hits development targets.

While the biologic is still in early-stage clinical testing as...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.